Live Breaking News & Updates on Apixaban

Stay informed with the latest breaking news from Apixaban on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Apixaban and stay connected to the pulse of your community

#VisualAbstract: Apixaban does not significantly prevent recurrent stroke after cryptogenic stroke in patients with atrial cardiopathy

Click here to read this study in JAMA. ©2024 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Minute-medicine-inc , Anticoagulation , Antiplatelet-therapy , Apixaban , Aspirin , Atrial-cardiopathy , Cardiopathy , Cryptogenic-stroke , Recurrent-stroke , Stroke , Stroke-prevention

Apixaban lowers the risk of stroke in subclinical atrial fibrillation

1. In this randomized controlled trial, apixaban lowered the risk of stroke or systemic embolism significantly more than aspirin in patients with subclinical atrial fibrillation. 2. Apixaban was associated with a higher risk of major bleeding than aspirin. Evidence Rating Level: 1 (Excellent) Study Rundown: Symptomatic atrial fibrillation is a leading cause of stroke and stroke-related

International-society-on-thrombosis , Minute-medicine-inc , Rating-level , Atrial-high-rate , International-society , Hazard-ratio , Confidence-interval , Apixaban , Atrial-fibrillation , Cardiology , Emergency

#VisualAbstract: Apixaban for Stroke Prevention in Subclinical Atrial Fibrillation

Click here to read this study in NEJM. ©2023 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Minute-medicine-inc , Anticoagulation , Apixaban , Aspirin , Atrial-fibrillation , Subclinical-atrial-fibrillation , Studygraphics ,

Major trial finds apixaban reduces stroke risk in patients with device-detected atrial fibrillation

The widely available blood thinner apixaban substantially reduced stroke in at-risk patients with a type of atrial fibrillation only detectable by a pacemaker or other implanted cardiac electronic device, a global study has found.

United-states , Canada , Canadian , American , Bristol-myers-squibb , Renato-lopes , Stuart-connolly , Jeff-healey , Population-health-research-institute , Canadian-institutes-for-health-research , Canadian-stroke-prevention-intervention-network , Pfizer-alliance

Journey to Anticoagulant Access Following Payer Rejection of Apixaban

Formulary restrictions can create treatment barriers for patients with atrial fibrillation, including unnecessary delays in treatment and prescription abandonment, with vulnerable populations at greater risk.

United-states , Louisiana , North-dakota , Greene , Minnesota , New-york , California , New-orleans , Olmsted-county , Lawrenceville , American , Americans

No benefit of low dose apixaban following acute COVID-19

The HEAL-COVID trial compared the efficacy of Apixaban to standard care in adults who have recently recovered from severe COVID-19.

United-states , United-kingdom , Northern-ireland , Craigavon , Scotland , National-institute-for-health , National-health-service , Discovery-industry-focus , National-institute , Care-excellence , Apixaban

Are non-vitamin K oral anticoagulants feasible for patients with atrial fibrillation on hemodialysis?

Germany: A recent study comparing apixaban and vitamin K antagonist (VKA) in atrial fibrillation (AF) patients on hemodialysis revealed no differences in safety or efficacy outcomes. AF patients on...

Safety-study-assessing-oral-anticoagulation , Vitamink-antagonists , Atrial-fibrillation , End-stage-kidney-disease , Randomized-controlled-trial-comparing-apixaban , Vitamink-antagonist-phenprocoumon , Chronic-hemodialysis , Apixaban , Irculation , Trial-fibrillation , Emodialysis

Myocarditis After COVID Vax; Cigar Sales in Convenience Stores

Also in TTHealthWatch: autoimmune disease treatment, and anticoagulant therapy in Afib

El-paso , Texas , United-states , Norway , Denmark , Norwegian , Rivaroxaban-xarelto , Rick-lange , Elizabeth-tracey , Pfizer , Texas-tech-university-health-sciences-center , Paull-foster-school-of-medicine

Statement on NIH starting enrollment for third trial of blood clotting treatments for COVID-19

Statement on NIH starting enrollment for third trial of blood clotting treatments for COVID-19
The National Institutes of Health has launched the last of three Phase 3 clinical trials to evaluate the safety and effectiveness of blood thinners to prevent life-threatening blood clots in adults diagnosed with COVID-19. The first patient in the trial was enrolled on February 15.
Part of the Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) initiative, the trial explores the use of Eliquis® (apixaban 2.5 mg), a blood thinner, or anticoagulant, donated by Bristol Myers Squibb/Pfizer, in patients who have been discharged from the hospital following a diagnosis of moderate-to-severe COVID-19, the disease caused by SARS-CoV-2.

Duke-university , North-carolina , United-states , Boston , Massachusetts , California , San-francisco , Ottawa , Ontario , Canada , Bristol-myers-squibb , University-of-california